These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 25944566)
1. BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells. Baker EK; Taylor S; Gupte A; Sharp PP; Walia M; Walsh NC; Zannettino AC; Chalk AM; Burns CJ; Walkley CR Sci Rep; 2015 May; 5():10120. PubMed ID: 25944566 [TBL] [Abstract][Full Text] [Related]
2. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells. Zanellato I; Colangelo D; Osella D Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341 [TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Lockwood WW; Zejnullahu K; Bradner JE; Varmus H Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19408-13. PubMed ID: 23129625 [TBL] [Abstract][Full Text] [Related]
5. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions. Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532 [TBL] [Abstract][Full Text] [Related]
9. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Yao W; Yue P; Khuri FR; Sun SY Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225 [TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470 [TBL] [Abstract][Full Text] [Related]
11. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
12. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. Liu X; Wu H; Huang P; Zhang F J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363 [TBL] [Abstract][Full Text] [Related]
13. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors. Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262 [TBL] [Abstract][Full Text] [Related]
14. EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1. Liu X; Li Q; Huang P; Tong D; Wu H; Zhang F J Cell Biochem; 2018 Oct; 119(10):8368-8377. PubMed ID: 30687956 [TBL] [Abstract][Full Text] [Related]
15. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL. Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638 [TBL] [Abstract][Full Text] [Related]
17. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878 [TBL] [Abstract][Full Text] [Related]
18. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
19. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling. Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436 [TBL] [Abstract][Full Text] [Related]